{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:14:04Z","timestamp":1790882044121,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Infusion reactions (IRs) are a significant concern in oncology due to unpredictable onset and a lack of standardized management guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare the incidence, severity and management of IRs related to chemotherapy and targeted therapies in real-world practice, based on the experience of Medical Day Hospital at the Fondazione IRCCS Istituto Nazionale Tumori in Milan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of 73,057 non-investigational drug preparations (39,468 chemotherapies; 33,589 targeted therapies) was conducted between 2020 and 2023. The primary endpoint was the incidence of IRs per administration. Statistical comparison was performed using the Chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 646 IRs were observed (0.88%). The median age was 61 years (range 19-90), 75 % female and 25% male. The incidence was significantly higher for chemotherapy (1.17%) compared to targeted therapies (0.55%; p &lt; 0.0001). The most problematic chemotherapies were paclitaxel (reaction risk 2.77%) and oxaliplatin (5.18%). For targeted therapies, rituximab (2.37%) and nivolumab (0.52%) showed the highest risk. Most reactions (97.4%) were mild (G1-G2) according to CTCAE 5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Chemotherapy remains associated with a significantly higher risk of IRs compared to targeted therapies. Although clinical presentations are similar, distinct pathophysiological mechanisms require tailored management and risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916261478866","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:06:31Z","timestamp":1790748391000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of infusion-related reactions to chemotherapy versus targeted therapy: A four-year experience at the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori Milano"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-3143","authenticated-orcid":false,"given":"Gabriella","family":"Mariani","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino Ippocrates","family":"Redaelli","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8692-9539","authenticated-orcid":false,"given":"Federica","family":"Manoni","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia Fiorella","family":"Dotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anna Maria","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events Version 5.0. November 27. Available at https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_application. (2017 accessed November 2025)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.01.020"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.90"},{"key":"e_1_3_2_5_2","first-page":"325","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel TT","year":"2010","unstructured":"Hansel TT, et al. The safety and side effects of monoclonal antibodies. Nat Rev 2010; 9: 325-338.","journal-title":"Nat Rev"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.01.012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32831961b3"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922"},{"key":"e_1_3_2_10_2","first-page":"28","article-title":"ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"1","author":"Rosell\u00f3 S","year":"2017","unstructured":"Rosell\u00f3 S, Blasco I, Garc\u00eda Fabregat L, et al. ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017; 1: 28.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14984"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60078-6"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1700\/1430.15808"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12437"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds314"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:24:3:253"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1263"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000324454"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3561"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.07.004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000178163"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916261478866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916261478866","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916261478866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:47:13Z","timestamp":1790880433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916261478866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":23,"alternative-id":["10.1177\/03008916261478866"],"URL":"https:\/\/doi.org\/10.1177\/03008916261478866","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"03008916261478866"}}